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Introduction {#sec1}
============

Neutrophils are the most abundant and short-lived human immune cells and are rapidly recruited to sites of infection as a first line of defense. Recently, they have attracted new attention with unexpected findings on their heterogeneity and plasticity ([@bib34]) and their ability to survive long term and shape adaptive immune responses ([@bib35]). With about 1 × 10^6^ neutrophils produced per second in the bone marrow (BM) of humans, granulopoiesis requires exquisite regulation. Multipotent progenitors (MPPs) give rise to granulocyte-monocyte progenitors (GMPs) and further to myeloblast cells (MBs), which are the first committed granulocyte precursors ([@bib4]). MBs proceed through promyelocyte (MC), metamyelocyte (MM), and band cell (BC) stages to become a mature polymorphonuclear neutrophil (PMN) ([@bib2]). This process is characterized by striking remodeling of the nucleus and temporally regulated granule generation by timed synthesis, which clearly demarcates stages of differentiation.

Recent advances have described the transcriptional networks that govern neutrophil differentiation in response to the granulocyte-colony stimulating factor (G-CSF) cytokine, but the mechanisms that enact these signals to enable differentiation remain poorly understood ([@bib6]).

Autophagy is a cellular recycling pathway that delivers diverse cytoplasmic material into double membraned autophagosome vesicles for lysosomal fusion and cargo degradation. This can free up essential metabolites for anabolic processes such as metabolic remodeling during differentiation ([@bib31]). Canonical macroautophagy (hereafter referred to as autophagy) has been demonstrated to be essential for terminal differentiation of several blood cell lineages ([@bib42]). For example, the metabolic adaptation and maintenance of terminal CD8^+^ memory and regulatory T cells both require autophagy ([@bib20], [@bib39], [@bib52], [@bib54]). While activated T cells preferentially engage glycolytic metabolism, memory and regulatory T cells switch to mitochondrial respiration for the bulk of ATP production ([@bib5], [@bib55]) and support this metabolic reprogramming by lipid breakdown and fatty acid oxidation (FAO) to supply acetyl-CoA metabolites for oxidative phosphorylation (OXPHOS) ([@bib36], [@bib38]). However, whether autophagy affects metabolic fuel choice either during hematopoietic progenitor or T cell differentiation remains unknown. The mitochondrial quality control through selective degradation of mitochondria (mitophagy) also contributes to metabolic adaptation during differentiation as was shown in innate NK lymphocytes ([@bib37], [@bib45]).

Autophagy-deficient neutrophils fail to mediate adequate inflammatory responses due to reduced degranulation, bacterial killing, and neutrophil extracellular trap (NET) formation ([@bib3], [@bib41]), while another study has found no functional neutrophil defects ([@bib44]). However, the role of autophagy in neutrophil differentiation is not understood.

Many acute myeloblastic leukemias (AMLs) are characterized by an accumulation of large numbers of granulocyte precursors, which engage aerobic glycolysis (Warburg metabolism), due to impaired differentiation ([@bib19], [@bib26]). Defective autophagy has been associated with myelodysplastic syndrome (MDS), its progression to AML, and excessive glycolysis ([@bib51]). Moreover, several drugs used to treat AML-affected patients also induce autophagy ([@bib1]). Therefore, understanding how autophagy affects normal neutrophil differentiation may have direct relevance to myeloid malignancies and potential therapeutic interventions.

Here, we show that autophagy is essential for neutrophil differentiation in a cell-intrinsic manner, *in vitro* as well as *in vivo*. We observed extensive metabolic reprogramming during normal differentiation, limiting glycolytic activity while engaging mitochondrial respiration and mobilizing intracellular lipid stores. Autophagy-deficient neutrophil precursors were unable to shift toward mitochondrial respiration and displayed excessive glycolysis, lipid droplet accumulation, and ATP depletion. Notably, inhibition of lysosomal lipolysis or fatty acid oxidation within mitochondria alone was sufficient to cause defective neutrophil differentiation. Importantly, administration of free fatty acids (FFAs) or pyruvate for mitochondrial respiration rescued differentiation in autophagy-deficient neutrophil precursors and restored normal glucose metabolism. Taken together, we show that autophagy-mediated lipid breakdown provides FFAs to support the FAO-OXPHOS pathway for ATP production, which is essential for neutrophil differentiation.

Results {#sec2}
=======

Dynamic Regulation of Autophagy Occurs during Early Neutrophil Differentiation {#sec2.1}
------------------------------------------------------------------------------

To understand the regulation of autophagy in normal neutrophil differentiation, we defined the five differentiation stages of myeloblasts (MBs), myelocytes (MCs), metamyelocytes (MMs), band cells (BCs), and neutrophils (PMNs) ([@bib46]) and confirmed those stages by morphology on Wright-Giemsa-stained cytospins ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#mmc1){ref-type="supplementary-material"}A), as well as by expression of relevant and stage-specific granule genes ([Figure 1](#fig1){ref-type="fig"}C). The expression of *Mpo*, a primary granule gene, is predominant in the early stages, whereas *Mmp9*, a tertiary granule gene, is expressed only at the band cell stage and later.Figure 1Autophagy during Normal GranulopoiesisBM neutrophil precursor populations from wild-type or *Map1lc3b*-GFP mice were separated by flow cytometry and analyzed for gene expression, morphology, and autophagy activity.(A) Gating strategy used to enrich populations of MBs, MCs, MMs, BCs, and PMNs as used in [Figures 1](#fig1){ref-type="fig"}, [3](#fig3){ref-type="fig"}, and [4](#fig4){ref-type="fig"}. MB, myeloblast; MC, myelocyte; MM, metamyelocyte; BC, band cell; PMN, polymorphonuclear neutrophil.(B) Representative Wright-Giemsa-stained cytospins from two experiments of sorted precursor stages for morphological validation. Scale bar, 25 μm.(C) Transcriptional expression of relevant primary (*Mpo*) and tertiary (*Mmp9*) granule genes relative to *Actin*. Data are shown as mean ± SEM (ΔΔCt) (n = 5--6 mice/group), representative of three experiments.(D) Representative histograms (left) of Map1lc3b-GFP fluorescence in flow cytometry-sorted neutrophil precursor populations from *Map1lc3b*-GFP transgenic mice. Autophagy flux (right) was measured by flow cytometry after treatment with vehicle or bafilomycin A1 (10 nM, 2 hr) calculated as (MFI (Bafilomycin A1--Basal) /MFI Basal) in two independent experiments.(E and F) Confocal microscopy of Map1lc3b-GFP fluorescence in flow cytometry-sorted precursors after treatment with vehicle or bafilomycin A1 (10 nM, 2 hr). Representative images (E), scale bar 5 μm, and quantification of LC3-II foci per cell (F).Data are shown as mean ± SEM (n = 3 mice) from three independent experiments. For all panels ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

To measure stage-specific autophagy activity *in vivo*, we took advantage of *Map1lc3b-*GFP transgenic mice ([@bib30]). When autophagosomal formation is induced, the small cytoplasmic protein Map1lc3b (hereafter referred to as LC3) is lipidated to LC3-II, which is incorporated into the autophagosomal membrane and routinely used to measure autophagy. Upon delivery of the autophagosomal content to the lysosome, LC3-II is degraded together with the cargo. If lysosomal degradation of LC3-II is inhibited by bafilomycin A1 (Baf), the build-up of LC3-II quantifies autophagic flux ([@bib22]). We found robust autophagic flux at the MB and MC stages, which decreased at the MM and BC stages and slightly increased again in mature PMNs ([Figure 1](#fig1){ref-type="fig"}D). Consistent with this, we found the expression of *Tfeb* (the master regulator of lysosomal and autophagy gene expression \[[@bib47]\]) as well as the essential autophagy gene *Atg7* to follow the same dynamic expression pattern ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Furthermore, we found the highest numbers of LC3-II puncta by confocal microscopy in MB and MC stages as well as in mature PMNs ([Figures 1](#fig1){ref-type="fig"}E and 1F). Lastly, we measured LC3-II by immunoblot in the well-established IL-3-dependent culture system 32D that mimics myeloblast to neutrophil differentiation *in vitro* in response to G-CSF ([@bib50]). In this model, uniform neutrophil differentiation could be followed over 5--7 days by expression of the maturation marker CD11b and nuclear morphology ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). As expected, we found the same pattern of dynamic regulation of autophagy---particularly at early differentiation stages---as we observed in primary cells ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Whereas the higher autophagy activity in the mature PMN stage is likely important in neutrophil function ([@bib3]), we hypothesized that autophagy in the early precursors may be relevant to the remodeling that occurs during differentiation.

Defective Autophagy Causes Accumulation of Immature Neutrophils and Neutrophil Dysfunction {#sec2.2}
------------------------------------------------------------------------------------------

To study the role of autophagy in early granulopoiesis *in vivo*, we used mice with a conditional deletion of the essential autophagy machinery component *Atg7*, under control of the pan-hematopoietic *Vav*-gene promotor (*Vav*-*cre* × *Atg7*^f/f^), resulting in deletion of *Atg7* at the hematopoietic stem and progenitor level ([@bib32]). We observed a profound ablation of *Atg7* expression (\>80%) by qPCR in mature neutrophils, their myeloblast precursors, and at the level of hematopoietic stem cells (HSCs) ([Figure S2](#mmc1){ref-type="supplementary-material"}A) as well as absence of Atg7 protein in Ly6G^+^ cells ([Figure 3](#fig3){ref-type="fig"}F). While neutrophils appeared expanded in *Vav*-*cre* × *Atg7*^f/f^ mice ([Figure 2](#fig2){ref-type="fig"}A), they expressed lower amounts of Ly6G ([Figure 2](#fig2){ref-type="fig"}B and quantified in [Figure S2](#mmc1){ref-type="supplementary-material"}C). Total Ly6G-expressing cells in the BM were expanded 2-fold and also significantly increased in spleen, blood, and peritoneum ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}B). We also observed a significant reduction in the phagocytic capacity of *Atg7*^*--/--*^ total Ly6G^+^ cells in response to LPS ([Figure 2](#fig2){ref-type="fig"}D). Moreover, and despite reduced phagocytosis, intracellular survival of *S. aureus* was significantly increased, indicating that autophagy-deficient neutrophils are also functionally defective ([Figure 2](#fig2){ref-type="fig"}E).Figure 2Acquisition of Terminally Differentiated Neutrophil Morphology and Function Requires AutophagyPhenotype of control and *Vav*-*cre*^+^ × *Atg7*^f/f^ (*Atg7*^--/--^) BM neutrophil populations.(A) Representative flow cytometry plots of Ly6G^+^SSC^hi^ BM neutrophil population from four independent experiments.(B) Representative histogram of Ly6G expression in BM from four independent experiments.(C) Absolute numbers of Ly6G^+^ cells in different tissues. Data are shown as mean ± SEM (n = 4--5 mice/group), representative of three experiments.(D) Phagocytosis was quantified as number of Ly6G^+^ cells that took up fluorescent latex beads during a 30 min culture period in the presence or absence of LPS. Data are shown as mean ± SEM (n = 4 mice/group), representative of three experiments.(E) Bacterial killing with Ly6G^+^ BM cells. Extracellular bacteria were removed by lysostaphin treatment (100 μg/mL) and live intracellular bacteria which escaped killing were measured as CFU × 10^3^/mL on agar plates. Data are shown as mean ± SEM (n = 3 mice/group). *S. aureus*, *Staphylococcus aureus*.(F) Gene expression was measured in isolated *Atg7*^--/--^ and *Atg7*^+/+^ Ly6G^+^ cells, *Mpo*, myeloperoxidase; *Mmp9*, matrix-metalloprotease 9. Data are shown as mean ± SEM (ΔΔCt) (n = 3 mice/group), representative of two experiments.(G) Electron micrographs were prepared to visualize *Atg7*^+/+^ and *Atg7*^--/--^ CD11b^+^ Ly6G^+^ BM cells (left), and number of nuclear lobes/section and granules were quantified (right). Scale bar, 2 μm.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

To address to what degree *Atg7*^*--/--*^ neutrophils were compromised in their differentiation, we further assessed their differentiation status. *Atg7*^*--/--*^ total Ly6G^+^ BM cells had increased *Mpo* and reduced *Mmp9* expression, a granule gene signature consistent with incomplete neutrophil differentiation ([Figure 2](#fig2){ref-type="fig"}F). In agreement, electron microscopy revealed a distinct reduction in electron-dense granules as well as reduced nuclear lobularization ([Figure 2](#fig2){ref-type="fig"}G). Notably, this morphological and functional dysregulation was also observed when only the Ly6G^hi^ fraction was specifically isolated by flow cytometry ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E). Thus, early *in vivo* deletion of the autophagy gene *Atg7* leads to accumulation of a phenotypically and functionally immature population of neutrophils.

Autophagy Is Essential for *In Vivo* Neutrophil Differentiation in a Cell-Intrinsic Manner {#sec2.3}
------------------------------------------------------------------------------------------

In order to conditionally delete *Atg7* specifically at the earliest neutrophil precursor stage but not in multipotent HSCs, we next generated mice with *Cebpa*-*cre*-driven excision of *Atg7*. *Cebpa* is reported to be expressed predominantly at the GMP stage, whereas there is negligible expression in HSCs or lymphoid lineages ([@bib53]). We confirmed by qPCR that while Atg7 mRNA was present in HSCs, it was profoundly reduced (\>90%) in GMP, MM, and PMN populations in *Cebpa*-*cre* × *Atg7*^f/f^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Complete absence of Atg7 protein was also confirmed by immunoblotting in total Ly6G^*+*^ BM cells ([Figure 3](#fig3){ref-type="fig"}A). As was seen in *Vav*-*cre* × *Atg7*^f/f^ mice, the Ly6G-expressing population was expanded ([Figure S3](#mmc1){ref-type="supplementary-material"}A) and retained a "left-shift" in morphology ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B) and granule gene expression ([Figure 3](#fig3){ref-type="fig"}C), resembling increased immature myeloblasts and myelocyte precursors.Figure 3Cell-Intrinsic, Atg5- and Atg7-Dependent Autophagy Is Essential for Neutrophil Differentiation(A) Immunoblot from Ly6G^+^ BM cells isolated from control (*Cebpa-cre*^--^) or *Cebpa-cre*^+^ × *Atg7*^f/f^ mice. Actin is used as loading control.(B) Representative images of Wright-Giemsa-stained cytospins of Ly6G^+^ cells (left) and histological quantification (right) of indicated maturation stages by morphology from n = 4--5 mice/group. Representative of two independent experiments. Scale bar, 25 μm.(C) mRNA expression of indicated genes in *Cebpa*-*cre*^+^ × *Atg7*^f/f^ Ly6G^+^ BM cells relative to control (*Cebpa-cre*^--^) Ly6G^+^ cells. *Mpo*, myeloperoxidase, primary granule; *Ltf*, lactoferrin, secondary granule; *Mmp9*, matrix-metalloprotease 9, tertiary granule. Data are shown as mean ± SEM (ΔΔCt) (n = 3--5 mice/group), representative of two experiments.(D) Abundance of cells expressing CD11b^+^Ly6G^+^ at surface relative to total lymphocytes (T + B cells, gated as CD3^+^ and CD19^+^, respectively) in PB of control (*Mx1*-*cre*^--^ × *Atg5*^f/f^) and *Mx1-cre*^+^ × *Atg5*^f/f^ chimeric mice at indicated time points. Data are shown as mean ± SEM (n = 6 mice/group), representative of two experiments. ^∗∗∗^p \< 0.001, tested by two-way ANOVA.(E) Wright-Giemsa-stained cytospins of Ly6G^+^ cells (left; scale bar, 25 μm) and histological quantification (right; per 100 total Ly6G^+^ cells) of indicated maturation stages by morphology after flow cytometric separation of CD45.2^+^ Ly6G^+^ cells, representative of two experiments.(F) Immunnoblot for Atg7 and LC3-I+II protein expression. Ly6G^+^ BM cells from *Vav*-*cre*^+^ × *Atg7*^f/f^ mice were used as control. Shown are three independent clones of wild-type (*Atg7*^+/+^) and CRSIPR-Cas9-generated *Atg7*^--/--^ genotypes grown clonally from sorted single cells.(G) Wright-Giemsa-stained cytospins of *Atg7*^+/+^ and *Atg7*^--/--^ cells after 5 days culture in G-CSF (100 nM) representative of three independent experiments. Scale bar, 50 μm.(H) Surface CD11b expression on *Atg7*^+/+^ and *Atg7*^--/--^ cells after 5 days in G-CSF-supplemented cultures. Unstained control cells from day 0 shown in gray. Representative of four independent experiments from three clones.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

While this suggests that the observed differentiation defect occurs in the earliest committed neutrophil precursors (MBs-MCs) as a result of autophagy deficiency, it remained possible that the Atg7-specific phenotype might be unrelated to autophagy. Second, defective differentiation may induce feedback granulopoiesis, through either intrinsic or extrinsic mechanisms, leading to secondary accumulation of neutrophil precursors. To address both issues, we generated mixed bone marrow chimeric mice with inducible deletion of *Atg5*, another essential autophagy gene ([@bib13]), under control of the *Mx1*-*cre* recombinase (*Mx1*-*cre* × *Atg5*^f/f^; *Atg5*^--/--^). Inducible deletion in the adult mouse after BM chimera generation also excludes potential effects of autophagy deletion during development or homing to the BM. Granulopoiesis was assessed after pIpC-induced deletion of *Atg5* by serial bleeding over 18 weeks in both *Atg5*^--/--^ and control BM chimera (experimental design shown in [Figure S3](#mmc1){ref-type="supplementary-material"}C). In mixed *Atg5*^--/--^ chimeras, the wild-type competitor cells gradually out-competed Atg5-deficient cells over time, as expected from the fundamental role of autophagy in self renewal of HSCs ([Figure S3](#mmc1){ref-type="supplementary-material"}D; [@bib32]). However, while the abundance of total Ly6G^+^ cells remained constant within CD45.2^+^ cells in control chimera, a significant increase in CD45.2^+^ (and not CD45.1^+^) Ly6G^+^ cells was observed over time in *Atg5*^--/--^ chimeras ([Figure 3](#fig3){ref-type="fig"}D). To assess their differentiation status, we isolated CD45.1^+^ and CD45.2^+^ CD11b^+^Ly6G^+^ cells by flow cytometry. Immature neutrophil precursors were dominant among the CD45.2^+^ but not among the CD45.1^+^ cells of the *Atg5*^--/--^ chimera, nor in any of the sorted populations of the control chimeric mice ([Figure 3](#fig3){ref-type="fig"}E). Together, our findings demonstrate that the differentiation block in autophagy-deficient neutrophils occurs at or after the GMP stage, is cell intrinsic, is not Atg7 specific, and occurs independent of the role of autophagy during development.

We next tested whether autophagy deficiency has an impact on the regulation of cytokine receptors, transcription factors, or granule genes that are key for neutrophil differentiation. Cebpa is the main transcription factor that acts at the GMP and MB stages to induce granulopoiesis and granule gene expression via G-CSF-receptor-mediated signaling ([@bib17], [@bib56]). While *Cebpa* expression was found highest at the MB and MC stages and then decreased over differentiation, it was not affected in *Atg7*^*--/--*^ animals ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Similarly, *Atg7* deletion did not affect granule gene transcription within isolated stages of neutrophil differentiation, and the cell surface expression of G-CSF and GM-CSF receptors was also unchanged in *Atg7*^*--/--*^ neutrophils ([Figures S3](#mmc1){ref-type="supplementary-material"}F and S3G). This confirms that the described differentiation defect is independent of Cebpa-dependent transcriptional events and that our finding of an immature gene signature among the total Ly6G^+^ population reflects a left shift toward immature stages. Lastly, we tested whether cell cycle exit was affected by the loss of autophagy as previously reported in other cell types ([@bib27]). Whereas the gradual cell cycle exit upon terminal neutrophil differentiation was confirmed by Ki67 flow cytometry, we found no impact on this in autophagy-deficient neutrophils ([Figure S3](#mmc1){ref-type="supplementary-material"}H).

To further pursue mechanistic studies and as myeloblasts and myelocytes are rare cell populations *in vivo*, we generated *Atg7*^*--/--*^ clones via CRIPSR/Cas9-mediated gene editing of the *in vitro* myeloblast line 32D (as in [Figure S1](#mmc1){ref-type="supplementary-material"}D). We targeted independent regions within the early exons 3 and 4 by specific sgRNAs. All independent clones showed complete absence of Atg7 protein as well as loss of autophagic flux, shown by lack of LC3-I to LC3-II conversion ([Figure 3](#fig3){ref-type="fig"}F). While LC3 is typically detectable only as lipidated LC3-II in 32D cells during homeostasis even when autophagy is low (as in [Figure S1](#mmc1){ref-type="supplementary-material"}E), absence of Atg7*-*mediated lipidation led to artificial LC3-I accumulation. Notably, in the presence of G-CSF, *Atg7*^+/+^ control myeloblasts upregulated the maturation marker CD11b normally and uniformly formed mature neutrophils within 5--7 days in the presence of G-CSF. In contrast, *Atg7*^--/--^ clones exclusively retained immature morphology with a lack of lobulated nuclei based on Wright-Giemsa-stained cytospins ([Figure 3](#fig3){ref-type="fig"}G) and had severely reduced CD11b expression ([Figures 3](#fig3){ref-type="fig"}H and [S3](#mmc1){ref-type="supplementary-material"}I). This *in vitro* system therefore confirms that the effect is a cell-intrinsic neutrophil differentiation defect as a consequence of autophagy deficiency at the committed neutrophil precursor stage.

Autophagy Is Essential for the Energy-Metabolic Reprogramming during Neutrophil Differentiation {#sec2.4}
-----------------------------------------------------------------------------------------------

Autophagy has been suggested to be important for metabolic homeostasis in T cells ([@bib39], [@bib54]), but the metabolic requirements during granulopoiesis are not known. We therefore first characterized the metabolic changes occurring during normal neutrophil differentiation by metabolomic analysis. We observed profound metabolic reprogramming during G-CSF-induced differentiation *in vitro*, as illustrated in the principal component analysis (PCA) of 4,215 metabolites ([Figure 4](#fig4){ref-type="fig"}A). In addition, *in vivo* transcriptional analysis of major metabolic enzymes within consecutive differentiation stages using the Fluidigm Biomark platform showed unsupervised clustering of individual granulopoietic stages, indicating a programmed metabolic remodeling ([Figure 4](#fig4){ref-type="fig"}B and [Table S1](#mmc1){ref-type="supplementary-material"}). While all 15 glycolytic pathway genes analyzed were downregulated during *in vivo* granulopoiesis ([Figure 4](#fig4){ref-type="fig"}B), the mitochondrial content simultaneously underwent a distinct 2-fold increase ([Figure 4](#fig4){ref-type="fig"}C). These results are consistent with a metabolic shift during granulopoiesis that limits glycolysis but engages mitochondrial respiration.Figure 4Autophagy Is Required to Maintain Metabolic Balance during Granulopoiesis(A, D, and E) Metabolites were extracted from 5 × 10^6^ cells of the indicated genotypes and metabolomic data were acquired by ICxMS/MS. Data from one experiment with six biological replicates.(A) Principal component analysis of myeloblasts after 2 and 5 days of G-CSF-induced differentiation (100 nM), scored based on the 4,215 detected metabolites (with Hotellings T2 ellipse at 0.95).(B) Microfluidic gene expression analysis with the Fluidigm-Biomark array for the indicated metabolic genes (100 cells/population) in five neutrophil differentiation stages sorted by flow cytometry from wild-type mouse BM. Unsupervised clustering of replicates based on z-score (n = 4 mice).(C) Mitochondrial content was quantified by flow cytometry from wild-type mouse BM as mitotracker green fluorescence intensity in indicated neutrophil precursor populations. Data are shown as mean ± SEM (n = 3 mice). ^∗∗∗^p \< 0.001, tested by one-way ANOVA.(D) Principal component analysis of *Atg7*^+/+^ myeloblasts and independent CRISPR *Atg7*^*--/--*^ clones, scored based on the 4,215 detected metabolites with %CV \< 30 on day 2 of G-CSF-induced differentiation.(E) Glycolysis metabolite abundance for control and CRISPR *Atg7*^--/--^ clones at the myeloblast stage cultured in IL-3. Heatmap shown as fold change normalized to wild-type abundance. Data represent six biological replicates per group from two independent clones. Seven of the ten glycolytic intermediates were detectable by mass spectrometry and are presented here.(F) Gene expression profiling of the glycolytic pathway was done using the Fluidigm Biomark 48 × 48 dynamic array on 100 purified precursor cells of each of the indicated differentiation stages purified by flow cytometry from *Atg7*^--/--^ and control *Atg7*^+/+^ BM. Data from three separate mice per genotype. Heatmaps are shown as fold change relative to *Actin* and normalized to *Atg7*^+/+^. All 15 glycolytic genes, except isoforms, were selected from the same gene panel as used in [Figure 4](#fig4){ref-type="fig"}B. Representative of three experiments.(G) Uptake of fluorescent glucose (2NBDG) during control and *Cebpa-cre*^+^ × *Atg7*^f/f^ neutrophil differentiation. Representative histogram (left) shows myelocyte (MC) population. Quantification (right) as geometric MFI ± SEM (n = 3 mice/group). Data from three individual experiments. ^∗^p \< 0.05, ^∗∗∗∗^p \< 0.0001, tested by two-way ANOVA.(H and I) Oxygen consumption rate (OCR) (H) and extracellular acidification rate (ECAR) (I) was measured under basal conditions and in response to indicated drugs. Data represent mean of four biological replicates from two independent CRISPR *Atg7*^*--/--*^ clones and *Atg7*^*+/+*^ controls at myeloblast stage cultured in IL-3.(J) Glycolysis and OXPHOS rates measured over 80 min as extracellular acidification (ECAR) and oxygen consumption (OCR), respectively, from *Atg7*^--/--^ and control *Atg7*^+/+^ freshly isolated Ly6G^+^ BM neutrophils. The ratio of OCR/ECAR was measured every 20 min ± SEM (n = 2 mice/group). Data representative of two experiments.(K) Cellular ATP was measured with a luciferase-assay from 1 × 10^6^ freshly isolated Ly6G^+^ BM neutrophils from control and *Atg7*^--/--^ mice (*Cebpa-cre*^+^ × *Atg7*^f/f^, n = 4 mice/group) and concentrations determined based on a standard curve.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Autophagy has been shown to regulate the balance of energy-generating metabolic pathways ([@bib28], [@bib9], [@bib11], [@bib51]). We therefore investigated the impact of Atg7 deficiency on these metabolic pathways. During G-CSF-induced differentiation, PCA showed a clear overall difference in the metabolome of *Atg7*^+/+^ and *Atg7*^--/--^ cells ([Figure 4](#fig4){ref-type="fig"}D). Of note, seven of the ten glycolysis intermediates were detectable by mass spectrometry, all of which were increased in *Atg7*^--/--^ myeloblasts compared to *Atg7*^+/+^ controls ([Figure 4](#fig4){ref-type="fig"}E).

We then extended this *ex vivo* finding to gene expression analysis of the glycolysis pathway in the five consecutive stages of neutrophil differentiation in *Atg7*^--/--^ BM neutrophil precursor populations. All differentiation stages showed elevated expression of a panel of 15 glycolysis genes in Atg7-deficient mice ([Figure 4](#fig4){ref-type="fig"}F and [Table S1](#mmc1){ref-type="supplementary-material"}). We next quantified the uptake of the fluorescent glucose analog 2NBDG and found *Atg7*^--/--^ precursors to have significantly increased uptake, particularly in the early MB and MC stages ([Figure 4](#fig4){ref-type="fig"}G).

Similarly, cultured control myeloblast clones showed decreasing expression of the glucose transporter Glut-1 and uptake of 2NBDG over the course of G-CSF-induced differentiation, while *Atg7*^--/--^ myeloblasts progressively increased both of these parameters during differentiation ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). The expression of key glycolytic genes also followed this trend ([Figure S4](#mmc1){ref-type="supplementary-material"}C) in *Atg7*^--/--^ cells. Glucose consumption and lactate production measured in the medium behaved similarly, with lactate production increased in *Atg7*^--/--^ myeloblasts both at early (day 2) and late (day 5) differentiation stages ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We also quantified the extracellular acidification rate (ECAR) and found basal glycolysis, maximal glycolytic capacity (after oligomycin treatment), and spare glycolytic capacity (Δafter oligomycin treatment) to be increased in *Atg7*^--/--^ myeloblasts ([Figures 4](#fig4){ref-type="fig"}H and [S4](#mmc1){ref-type="supplementary-material"}E). In contrast, quantification of oxygen consumption rate (OCR) showed a decrease in basal respiration, spare respiratory capacity (Δafter FCCP treatment), and mitochondrial ATP production (Δafter oligomycin treatment) in *Atg7*^--/--^ myeloblasts ([Figures 4](#fig4){ref-type="fig"}I and [S4](#mmc1){ref-type="supplementary-material"}F). Notably, this was confirmed in *ex vivo* Ly6G^+^ *Atg7*^--/--^ neutrophils showing increased basal ECAR and decreased OCR ([Figure 4](#fig4){ref-type="fig"}J) with significantly reduced ATP ([Figure 4](#fig4){ref-type="fig"}K). The compensatory glycolysis during *Atg7*^--/--^ neutrophil differentiation was further confirmed by the increased expression of *Ldha* and decreased expression of *Ldhb* in early precursors ([Figure S4](#mmc1){ref-type="supplementary-material"}G), switching from pyruvate use in the TCA cycle to generating lactate and NAD^+^ to keep glycolysis going. Thus, the metabolic switch that occurs during granulopoiesis is cell intrinsic, conserved *in vivo* and *in vitro*, and depends on autophagy to limit glycolysis but rather engage mitochondrial respiration.

Autophagy Degrades Lipid Droplets during Neutrophil Differentiation {#sec2.5}
-------------------------------------------------------------------

We hypothesized that, as glycolysis decreases during neutrophil differentiation, breakdown of lipids for FAO might take over to support mitochondrial respiration and ATP production. Autophagy was recently identified as a major pathway for lipid breakdown in hepatocytes by targeting lipids into autophagosomes for hydrolyzation via lysosomal lipases (lipophagy), yielding FFAs ([@bib48]). Indeed, we found a depletion of free fatty acids, in particular palmitic, oleic, and eicosanaic acids by lipdomics in *Atg7*^--/--^ myeloblasts ([Figure 5](#fig5){ref-type="fig"}A). In addition, we found accumulation of vesicles in the Wright-Giemsa cytospins from *in vitro* cultured *Atg7*^--/--^ neutrophils after G-CSF-induced differentiation ([Figure 5](#fig5){ref-type="fig"}B, top), which were confirmed to be of lipid origin upon staining with the neutral lipid-specific dye Bodipy ([Figure 5](#fig5){ref-type="fig"}B, bottom). In parallel we used Bodipy to label lipid droplets for quantitative flow cytometry on different days after addition of G-CSF and confirmed this with Nile Red, another well-established marker for lipid droplets. Lipid droplet amount decreased during *Atg7*^+/+^ myeloblast differentiation *in vitro*, while *Atg7*^--/--^ neutrophils progressively accumulated lipids ([Figures 5](#fig5){ref-type="fig"}C and 5D). Increased number of lipid droplets per cell was also confirmed in *ex vivo* sorted Ly6G^+^ *Atg7*^--/--^ neutrophils from BM by fluorescent microscopy ([Figure 5](#fig5){ref-type="fig"}E). Similarly, *Atg5*^*--/--*^ neutrophils from *Cebpa-cre* × *Atg5*^f/f^ mice showed increased lipid droplets by fluorescent microscopy ([Figure 5](#fig5){ref-type="fig"}F). Bodipy staining by flow cytometry confirmed that lipid droplets decreased slightly during *Atg7*^+/+^ neutrophil differentiation *in vivo* while they accumulated progressively in *Atg7*^--/--^ neutrophils over their differentiation ([Figure 5](#fig5){ref-type="fig"}G). Finally, we observed colocalization of autophagosomes with lipid droplets in sorted BM progenitors by confocal microscopy ([Figure S5](#mmc1){ref-type="supplementary-material"}A) and observed the formation of membrane structures with more than one layer around lipid droplets on electron micrographs ([Figure S5](#mmc1){ref-type="supplementary-material"}B) as previously described ([@bib48]). We conclude that degradation of lipid droplets during normal neutrophil differentiation is mediated by autophagy to maintain the pool of cytosolic FFAs while preventing lipid accumulation.Figure 5Autophagy Mediates Lipolysis during Neutrophil Differentiation(A) Free fatty acid abundance in *Atg7*^+/+^ and CRISPR-*Atg7*^--/--^ clones quantified by GCxGC/MS. Data represent 5--6 biological replicates per genotype from two independent clones. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.(B) Wright-Giemsa-stained cytospins (top) and confocal micropgraphs (bottom) from two independent experiments showing lipid droplets stained with Bodipy 493/503 (1 ng/mL) in *Atg7*^+/+^ and CRISPR-*Atg7*^--/--^ clones after culture in G-CSF (100 nM) for 5 days; arrows indicate lipid droplets. Scale bar, 5 μm.(C and D) Representative histograms (left) and geometric MFI (right) from two experiments showing (C) Bodipy and (D) Nile red lipid-droplet dye in *Atg7*^+/+^ and *Atg7*^--/--^ myeloblasts after the indicated duration of G-CSF (100 nM)-induced differentiation. Histograms are from day 5, gray is unstained control from day 0. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, tested by two-way ANOVA.(E and F) Nile red^+^ Bodipy^+^ lipid droplets were quantified by confocal microscopy in isolated total Ly6G^+^ BM cells from (E) *Atg7*^+/+^ and *Atg7*^--/--^ mice or (F) *Atg5*^+/+^ and *Atg5*^--/--^ mice (*Cebpa-cre*^+^ × *Atg5*^f/f^). Confocal micrographs (left; scale bar, 5 μm) and quantification as lipid droplets/cell ± SEM (right). Data in (E) are combined from two independent experiments (n = 3 mice). ^∗^p \< 0.05, ^∗∗^p \< 0.01.(G) Representative histograms of Bodipy fluorescence in *Atg7*^+/+^ and *Cebpa-cre*^+^ × *Atg7*^f/f^ (*Atg7*^--/--^) precursors (left) and quantification of lipid droplets as the geometric MFI ± SEM from the indicated *Atg7*^+/+^ and *Atg7*^--/--^ BM precursor populations (n = 3 mice), representative of three independent experiments. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, tested by two-way ANOVA.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Notably, all stages of neutrophil differentiation, in particular the earliest stages with highest autophagy, expressed the cell surface FFA transporter CD36, demonstrated active uptake of FFAs, and also expressed the gene encoding fatty acid synthase (*Fasn*) ([Figures S5](#mmc1){ref-type="supplementary-material"}C--S5E). Yet, total lipid content decreased during granulopoiesis, confirming active lipolysis. Pharmacological inhibition of FFA synthesis by C75 or the CD36 inhibitor SSO ([@bib7], [@bib25]), however, did not inhibit neutrophil maturation ([Figure S5](#mmc1){ref-type="supplementary-material"}F), suggesting that neutrophils may have redundant pathways to maintain their lipid reserves.

Lipophagy Is Required for Neutrophil Metabolic Adaptation and Differentiation {#sec2.6}
-----------------------------------------------------------------------------

We next addressed whether the defect in supply of FFAs for FAO and OXPHOS could be causative for the metabolic rewiring and the neutrophil differentiation defect in Atg7-deficient mice. We first tested whether defective lipolysis is sufficient to block neutrophil differentiation, by differentiating myeloblasts with G-CSF in the presence of the pan-lipase inhibitor DEUP, the lysosomal lipase (LAL) inhibitor orlistat, or the FAO inhibitor etomoxir. As expected, all three drugs led to an increase in lipid droplets ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). Both lipase inhibitors DEUP and orlistat also increased glycolysis as measured by 2NBDG uptake ([Figure 6](#fig6){ref-type="fig"}A), lactate production, and glucose consumption ([Figure S6](#mmc1){ref-type="supplementary-material"}D), supporting our finding that defective lipolysis signals for a glycolytic shift in metabolism when autophagy is disrupted. In further support of a causative role for this metabolic shift in disrupting differentiation of autophagy-deficient neutrophils, all three drugs led to a partial but significant inhibition of differentiation as seen by a decrease in the maturation marker CD11b ([Figure 6](#fig6){ref-type="fig"}B) and an increase in myeloblast-like morphology ([Figure 6](#fig6){ref-type="fig"}C). Lastly, wild-type 32D myeloblast differentiation was not affected by the cytosolic Atgl-lipase inhibitor atglistatin ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Taken together, both active lysosomal lipolysis and their subsequent oxidation in mitochondria are required for normal neutrophil differentiation and to prevent excessive glycolysis.Figure 6Lysosomal Lipolysis and FAO Are Required for Neutrophil Metabolic Switch and DifferentiationWild-type myeloblasts were treated with LAL-inhibitor orlistat (100 μM), lipase inhibitor DEUP (5 μM), FAO-inhibitor etomoxir (60 μM), or vehicle control during 5 days of G-induced differentiation. Data representative of three experiments.(A) Histograms (left) and quantification (right) of fluorescent glucose (2NBDG) uptake as geometric MFI ± SEM from four replicates on day 5 of G-CSF treatment.^∗^p \< 0.05, ^∗∗∗^p \< 0.01.(B) Histograms (left) and quantification (right) of CD11b maturation marker expression on day 5 of G-CSF-induced differentiation. Ctrl in gray are mature control cells (G-CSF day 7). Quantification shown as mean (±SD) percent of cells CD11b^hi^ from four biological replicates, representative of three independent experiments.(C) Wright-Giemsa-stained cytospins after inhibitor treatment over 5 days of G-CSF-induced differentiation. Arrows indicate lipid droplets; scale bar, 50 μm.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Free Fatty Acids and Pyruvate Are Sufficient to Restore Differentiation in Autophagy-Deficient Neutrophil Precursors {#sec2.7}
--------------------------------------------------------------------------------------------------------------------

To confirm whether FFAs provided by lipophagy are necessary for normal neutrophil differentiation and metabolic homeostasis, we attempted to rescue differentiation of *Atg7*^--/--^ neutrophil precursors by providing exogenous FFAs, known to be broken down for FAO. While linoleic acid (LA) has been shown to improve mature neutrophil function ([@bib43]), there have been no data implicating it in neutrophil differentiation. We treated *Atg7*^+/+^ and CRISPR-*Atg7*^--/--^ myeloblasts with LA or a mixture of saturated and unsaturated FFAs during G-CSF-induced differentiation. Both conditions led to an almost complete resolution of the increased glucose uptake ([Figure 7](#fig7){ref-type="fig"}A) and of the defective neutrophil differentiation of *Atg7*^*--/--*^ myeloblasts ([Figures 7](#fig7){ref-type="fig"}B--7D). To determine whether fatty acids are used during neutrophil differentiation as energy substrates for FAO and OXPHOS, we also tested whether pyruvate, an energy metabolite that can substitute fatty acid-derived acetyl-CoA to directly fuel OXPHOS, also can rescue *Atg7*^--/--^ differentiation. Pyruvate treatment alone was sufficient to restore differentiation of *Atg7*^--/--^ myeloblasts as measured by CD11b expression ([Figure S7](#mmc1){ref-type="supplementary-material"}A) and nuclear morphology ([Figures 7](#fig7){ref-type="fig"}C and [S7](#mmc1){ref-type="supplementary-material"}B).Figure 7Free Fatty Acids Restore Glucose Metabolism and Differentiation in Autophagy-Deficient Neutrophil Precursors*CRISPR-Atg7*^+/+^ and *Atg7*^--/--^ myeloblasts were cultured for 5 days in G-CSF (100 nM) to induce differentiation in the presence of linoleic acid (LA) (10 μg/mL), a mix of saturated and non-saturated fatty acids (FFA mix) (10 μg/mL fatty acids), or vehicle control. Data representative of two experiments.(A) Quantification of fluorescent glucose (2NBDG) uptake as geometric MFI ± SEM from three independent cultures.(B) Quantification of indicated maturation stages by morphology. Data are shown as number of cells per 100 cells counted combined from two individual experiments, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(C) Representative Wright-Giemsa-stained cytospins from two independent experiments from (B). Scale bar, 50 μm.(D) Histograms (left) and quantification (right) of CD11b maturation marker expression after day 5 of the indicated treatment in the presence of G-CSF, quantified as mean ± SEM from three biological replicates, ^∗∗^p \< 0.01.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Taken together, administration of free fatty acids is sufficient to restore normal glucose metabolism and rescue differentiation in autophagy-deficient neutrophil precursors. The OXPHOS-fueling substrate pyruvate similarly restores differentiation, supporting that lipophagy provides FFAs for mitochondrial ATP generation in order to drive normal neutrophil differentiation.

Discussion {#sec3}
==========

Here we show that autophagy is essential for normal neutrophil differentiation *in vivo*. Our results further show that autophagy provides FFAs via lipid droplet degradation in order to maintain energy-metabolic balance. We conclude that the autophagy-controlled FAO-OXPHOS pathway may be critical to supply sufficient ATP for the energy-demanding process of differentiation.

A couple of pioneering studies describe an essential role for autophagy in the myeloid lineage during monocyte to macrophage differentiation by preventing caspase-mediated cell death ([@bib18], [@bib57]). We propose that autophagy may also play a role in sustaining energy metabolism in the monocyte-macrophage lineage differentiation. Supporting this view, work by Ed Pearce et al. demonstrates that the differentiation from monocytes into M2 macrophages requires a shift to OXPHOS which depends on the lysosomal lipase (LAL) ([@bib16]). In addition, in line with our findings, LAL-deficient mice show a similar increase in immature granulocytes as seen in our mouse models, compatible with a defect in granulopoiesis ([@bib40]).

Studies of neutrophil differentiation have so far been limited by the availability of a suitable *cre* system to excise with specificity at the earliest precursor stage. Deleting *Atg7* within HSCs caused expansive myelodysplastic disease and bone marrow failure in mice ([@bib33]), while *Lyz2-cre*-mediated deletion is inefficient in granulocyte precursors. Accordingly, *Lyz2-cre*-mediated *Atg5* deletion had no measurable impact on neutrophil function but caused a mild expansion of precursors ([@bib44]). Herein we used the *Cebpa* promotor to drive robust *cre*-mediated excision of *Atg7* in \>90% of GMP-MB-stage neutrophil precursors, enabling us to study autophagy during early granulopoiesis independent of a defect at the HSC level.

Neutrophil differentiation is driven by G-CSF that signals though the G-CSF receptor for a distinct transcriptional program. Here we have shown that autophagy adds another, metabolic, layer to this purely genetic control of differentiation. Notably, autophagy does not appear to interfere with the rewiring of the transcriptional program, as expression of gene regulators (*Cebpa*) and granule genes is the same in neutrophil precursors at distinct stages regardless of their autophagy status. Because we find a population that expresses Ly6G but has remained morphologically (i.e., fail to segment their nuclei) and functionally (unable to phagocytose) immature, the requirement for autophagy in cellular differentiation may occur in parallel and independent of transcriptional regulators.

A causal link has been implicated between autophagy, metabolism, and differentiation outside of the hematopoietic system, in hepatic stellate cells. Autophagy is critical in the transdifferentiation of hepatic stellate cells into proliferative myofibroblasts, and the addition of FFA rescued the differentiation of autophagy-deficient hepatocytes ([@bib15]). Together with our data this suggests that the mechanism described here operates broadly and perhaps universally in cellular differentiation. Notably, the CMA-dependent degradation of lipid droplet-associated proteins such as perilipin 2 (PLIN2) and PLIN3 precedes and facilitates lipolysis in fibroblasts ([@bib21]), demonstrating the existence of an intimate crosstalk between different forms of autophagy in the control of intracellular homeostasis.

While the excessive glycolysis in autophagy-deficient precursors is likely a secondary compensation effect to alleviate the energy crisis, it does not restore ATP balance back to wild-type amounts nor does it restore differentiation. However, exogenous pyruvate at supraphysiological amounts or the addition of free fatty acids (either linoleic acid or a mixture of free fatty acids) restore differentiation. Together, this indicates that in the absence of autophagy, either of these metabolites can correct the energy-metabolic requirements for neutrophil differentiation.

In addition to fatty acid delivery, autophagy is central to FAO and OXPHOS by maintaining mitochondrial health via mitophagy. For example, virus-specific NK cell differentiation into long-lived memory cells requires Bnip3- and Bnip3L-driven mitophagy for mitochondrial maintenance and prevention of ROS ([@bib37]). While defective mitochondrial turnover and health may also contribute to the observed neutrophil differentiation defect in *Atg7*^--/--^ and *Atg5*^--/--^ models, we were unable to improve differentiation with the antioxidant NAC and Bnip3-null mice develop morphologically normal neutrophils ([@bib10]). Whereas Bnip3 deletion allowed targeted disruption of the mitophagy pathway, the receptor that delivers lipid droplets into autophagosomes has not yet been identified. Its identification would enable further insight into the relevance and mechansims of autophagy-mediated lipolysis.

Many myeloid leukemias are characterized by defective granulocyte differentiation with myeloblast accumulation, dysregulated autophagy-gene expression, and Warburg-like aerobic glycolysis, although a causative link between these findings remains to be established. It would therefore be of interest to investigate whether a similar metabolic rewiring dependent on autophagy to provide free fatty acids for FAO and OXPHOS is active during leukemogenesis, potentially caused by the extreme energy demands associated with ongoing proliferation and anabolism in leukemia ([@bib8]). The establishment of autophagy and energy-metabolic adaptation as unique critical regulators of normal granulopoiesis and their mechanistic interaction for an autophagy-FAO-OXPHOS pathway may also be relevant in the context of congenital or radiation-therapy-induced neutropenia.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**PE anti-mouse CD34 Antibody, Clone HM34BioLegendCat\#152204; RRID: [AB_313659](nif-antibody:AB_313659){#intref0010}PE/Cy7 anti-mouse Ly-6G Antibody, Clone 1A8BioLegendCat\#127618; RRID: [AB_1877261](nif-antibody:AB_1877261){#intref0015}APC/Cy7 anti-mouse CD117 (c-kit) Antibody, Clone 2B8BioLegendCat\#105826; RRID: [AB_2632809](nif-antibody:AB_2632809){#intref0020}APC anti-mouse TER-119/Erythroid Cells Antibody, Clone Ter119BioLegendCat\#116212; RRID: [AB_313713](nif-antibody:AB_313713){#intref0025}PE anti-mouse CD11b Antibody, Clone M1/70BioLegendCat\#101208; RRID: [AB_312790](nif-antibody:AB_312790){#intref0030}APC anti-mouse/human CD45R/B220 AntibodyBioLegendCat\#103212; RRID: [AB_312996](nif-antibody:AB_312996){#intref0035}APC anti-mouse CD8a Antibody, Clone 53-6.7BioLegendCat\#100712; RRID: [AB_312751](nif-antibody:AB_312751){#intref0040}APC anti-mouse CD19 Antibody, Clone 6D5BioLegendCat\#115511; RRID: [AB_313646](nif-antibody:AB_313646){#intref0045}Anti-mouse monoclonal G-CSF R/CD114 Antibody (723806); Alexa Fluor-405R&D SystemsCat\#MAB6039; RRID: [AB_10890232](nif-antibody:AB_10890232){#intref0050}APC anti-mouse CD4 Antibody, Clone GK1.5BioLegendCat\#100412; RRID: [AB_312696](nif-antibody:AB_312696){#intref0055}Alexa Fluor 488 anti-mouse CD36 Antibody, Clone G8.8BioLegendCat\#102607; RRID: [AB_1134107](nif-antibody:AB_1134107){#intref0060}**Bacterial and Virus Strains***Staphylococcus aureus*ATCCATCC 29213**Chemicals, Peptides, and Recombinant Proteins**May Grünwald Wright Giemsa stainThermo ScientificCat\#69027Glut1.RBD reagent GFP labeledMetafloraCat\#Glut1-G25Recombinant murine IL-3PeprotechCat\#213-13-100Recombinant murine G-CSFPeprotechCat\#250-05-100Lysostaphin from StaphylococcusSigma AldrichCat\#L7386Etomoxir sodium salt hydrateSigma AldrichCat\#E1905Diethyl-umbelliferyl phosphateSigma AldrichCat\#D7692OrlistatSigma AldrichCat\#O4139TaqMan Gene Expression Master MixLife TechnologiesCat\#4369016**Critical Commercial Assays**ATP BIOLUMINESCENCE ASSAY KIT HS IISigma AldrichCat\# 11699709001Anti-Ly-6G MicroBead Kit, mouseMiltenyi BiotecCat\#130-092-332SuperScript III Platinum One-Step qRT-PCR KitThermo FisherCat\#11732020Glycolysis Cell-Based Assay KitCambridge BioscienceCat\#600450Seahorse CF Cell Mito and Glycolysis Stress Test KitsAgilentCat\#103015GLUCOSE (GO) Assay kitSigma AldrichCat\#GAGO20**Experimental Models: Cell Lines**32Dcl3 Cell lineATCCATCC; CRL-11346\
RRID; CVCL_0119**Experimental Models: Organisms/Strains**Mouse; *Atg7* flox, Atg7^tm1Tchi^; B6.Cg-Atg7 \< tm1Tchi \>[@bib23]MGI: [3587769](mgi:3587769){#intref0065}Mouse; *Atg5* flox, B6.129S-Atg5 \< tm1Myok \>RikenRBRC: 02975Mouse; *Mx1-cre*; C.Cg-Tg(Mx1-cre)1Cgn/JJackson LaboratoriesJAX: \#005673Mouse; *Vav-cre*; B6.Cg-Tg(Vav1-icre)A2Kio/JJackson LaboratoriesJAX: \#008610Mouse: *Cebpa-cre*; Cebpa^tm1.1(cre)Touw^[@bib53]MGI: [4867437](mgi:4867437){#intref0070}**Oligonucleotides***Mx1Cre* 1 5′ -CAT GTG TCT TGG TGG GCT GAG-3′Sigma OligoN/A*Mx1Cre* 2 5′ -CGC ATA ACC AGT GAA ACA GCA T-3′Sigma OligoN/A*CebpaCre* FW: 5′ -CGA TGC AAC GAG TGA TGA GGT TC-3′Sigma OligoN/A*CebpaCre* RV: 5′ -GCA CGT TCA CCG GCA TCA AC-3′Sigma OligoN/A*Atg7* WT PCR 5′ -CCA TGC TGA TGG CTA ATG TCT C- 3′Sigma OligoN/A*Atg7* flox FW 5′ -CTG CAG GAA TTC GAT ATC ATA ACT TCG- 3′Sigma OligoN/A*Atg7* flox RV 5′ -GTC CAG AGT CCG GTC TCT GGT TG- 3′Sigma OligoN/A*Atg5* flox Primer A 5′-GAA TAT GAA GGC ACA CCC CTG AAA TG-3′Sigma OligoN/A*Atg5* flox Primer B 5′-GTA CTG CAT AAT GGT TTA ACT CTT GC-3′Sigma OligoN/A*Atg5* flox Primer C 5′-ACA ACG TCG AGC ACA GCT GCG CAA GG-3′Sigma OligoN/A**Software and Algorithms**Graphpad Prism v. 7[www.graphpad.com](http://www.graphpad.com){#intref0075}N/AFlowJo v. 10[www.flowjo.com](http://www.flowjo.com){#intref0080}N/AR version 3.3.3<https://www.r-project.org/>N/AFiji<https://fiji.sc>N/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Katja Simon (<katja.simon@kennedy.ox.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

*Cebpa*-*cre* mice ([@bib53]) were from Prof. Ivo Touw and crossed with *Atg7*^*f/f*^ ([@bib23]) or *Atg5*^*f/f*^ ([@bib13]) mice to obtain *Cebpa-cre*^+^ x *Atg7*^f/f^ and *Cebpa-cre*^+^ x *Atg5*^f/f^ mice. *Vav*-*cre* and *Mx1*-*cre* mice were crossed with *Atg7*^*f/f*^ and *Atg5*^*f/f*^ mice, respectively, to generate *Vav*-*cre* x *Atg7*^f/f^ and *Mx1*-*cre*^+^ x *Atg5*^f/f^ mice. *Cre*^--^ x *Atg7*^f/f^ mice were used in all experiments as controls and were littermates. Male and female mice were used at equal numbers at the age of 6-10 weeks and did not undergo previous procedures except were indicated. C57BL/6 SJL CD45.1 mice for bone marrow chimeras were purchased from Biomedical Services, Oxford. All mice were fully backcrossed to C57BL/6 and housed under specific pathogen-free conditions, up to 7 mice per cage, at Biomedical Services Oxford, and fed standard pellet chow and reverse osmosis water *ad libitum*. Animal experiments were approved by the local ethical review committee and performed under UK project license PPL 30/3388.

### Cell lines {#sec4.3.2}

32D-cl3 (32D) myeloblast cells, RRID CVCL_0119, are derived from *Mus musculus*, were purchased from ATCC and cultured in RPMI 1640 with 10% FCS, 2 mM L-glutamine,100 U/ml Pen-Strep, and 10 ng/ml IL-3 at 37°C, 5% CO~2~. The sex of this cell line is unknown.

Method Details {#sec4.4}
--------------

### 32D CRISPR *Atg7*^--/--^ myeloblast clone generation {#sec4.4.1}

Using 32D-cl3 cells, three independent CRISPR *Atg7*^--/--^ clones were generated with sgRNAs from dsODN into pX458 (Feng Zhang, Addgene 48138) plasmids and individually tested in Surveyor assays. Different regions in exons 3-4 of the *Atg7* gene were targeted by plasmid transfection via electroporation and single cells were flow-sorted based on GFP-expression 3 days later. Single cell-derived clones were grown in IL-3 supplemented medium and frameshift deletion confirmed by target site sequencing and western blotting.

### Generation of bone marrow chimeric mice {#sec4.4.2}

For *Atg5*^f/f^ x *Mx1*-*cre* (pIpC inducible) chimeras, BM was extracted from tibia and femur of a single 8-week old *Atg5*^f/f^ x *Mx1*-*cre*^--^, *Atg5*^f/f^ x *Mx1*-*cre*^+^ (both CD45.2^+^), and C57BL/6 SJL mouse (CD45.1^+^). 2x10^6^ CD45.2^+^ BM cells were added to 2x10^6^ CD45.1^+^ BM cells (1:1 CD45.2^+^:CD45.1^+^) in a total volume of 200 μL PBS. The 1:1 BM mix was injected i.v 2h after lethal irradiation (450cGy twice, 4 hours apart) into lethally irradiated C57BL/6 SJL CD45.1^+^ recipient mice. 6 weeks post-transplantation, mice were injected i.p. with 250 μg pIpC in 250 μL saline or 250 μL PBS to induce expression of *Mx1*-*cre* and monitored over a time of 18 weeks. After 18 weeks, BM was extracted and analyzed by flow cytometry. Chimeric mice that received *Atg5*^f/f^ *Mx1*-*cre*^--^ donor type cells (CD45.2) were termed control chimera, mice with Atg5^f/f^ *Mx1*-*cre*^+^ CD45.2 cells were termed Atg5-deficient chimera (*Atg5*^--/--^). This experiment was repeated twice.

### *In vitro* neutrophil differentiation assays {#sec4.4.3}

For neutrophil differentiation, 32D-cl3 (32D) myeloblast cells were washed twice with 50 mL PBS to remove IL-3 and resuspended at 2 × 10^5^ cells/ml in medium containing 100 ng/ml recombinant murine G-CSF (peprotech). In experiments involving drug treatments, orlistat (100 μM), methyl-pyruvate (2 mM), di-ethyl-umbelliferyl-phosphate (DEUP, 20 μM), etomoxir (60 μM), C75 (10 μM), SSO (100 μM), linoleic acid (10 μg/ml), FFA mix (10 μg/ml each linoleic, linolenic, myristic, oleic, palmitic and stearic acids + 0.22 mg/ml cholesterol) (all from Sigma) were added to the cells in G-CSF containing differentiation medium for the time indicated. Controls were treated with appropriate vehicle (H~2~O, PBS or DMSO). DEUP has been shown to inhibit the neutral cholesteryl ester hydrolase activity responsible for hydrolysis of cellular lipid droplet cholesteryl esters ([@bib14]). Orlistat is an irreversible, selective inhibitor of serine-containing active site triglyceride lipases ([@bib12]). Etomoxir (2\[6(4-chlorophenoxy)hexyl\]oxirane-2-carboxylate) is an irreversible inhibitor of carnitine palmitoyltransferase-1 on the outer face of the inner mitochondrial membrane ([@bib24]). Atglistatin is a selective small molecule inhibitor for the rate limiting cytosolic triglyceride lipase *Atgl* ([@bib29]). Sulfo-N-succinimidyl oleate (SSO) allosterically inhibits the uptake of fatty acids via FAT/CD36 ([@bib7]). C75 is a chemically stable synthetic inhibitor of fatty acid synthase (*fasn*) ([@bib25]). All cell culture experiments included at least three biological replicates per experiment and were repeated twice, unless stated otherwise in figure legends.

### Flow cytometry {#sec4.4.4}

Fluorochrome-conjugate monoclonal antibodies were purchased from eBioscience, BD Bioscience, or Biolegend. Total Ly6G^+^ cells (which include MM, BC, PMN) were purified using MACS columns were indicated. Staining was performed as previously described ([@bib39]). GLUT-1 was measured through binding to its ligand, the receptor binding domain (RBD) of a recombinant glycoprotein from the human T lymphotrophic virus (HTLV) fused to eGFP (RBD-eGFP, Metaflora). For mitochondrial mass analysis, cells were stained with MitoTracker Green (Life Technologies) at 150 nM in PBS, 2% FCS for 30 min at 37°C after surface antibody staining. For glucose uptake measurements, cells were incubated in media containing 50 μg/ml 2-NBDG for 20 min at 37°C after surface antibody staining. For lipid droplet quantification, cells were incubated in media containing 1000 ng/ml Bodipy at 37°C for 30 min. Cells were analyzed using Canto III or LSR II flow cytometers (BD Biosciences). All flow cytometry experiments included at least three biological replicates per experiment and were repeated at least twice, unless stated otherwise in figure legends.

### Metabolomic analysis by LC/MS/MS and GC/GC/MS {#sec4.4.5}

Metabolites were extracted from 5x10^6^ cells of the indicated genotype and differentiation stages (grown in cell culture flasks) by addition of 500 μL of ice cold 80% aqueous methanol. The supernatants were combined and filtered using a 3KD ultrafilter (Millipore), dried in a SpeedVac and subsequently stored at −80°C. On the day of analysis, the dried extracts were re-constituted in 60 μL of ice cold 80% aqueous methanol. A quality control (QC) sample was made by combing 5 μL of each sample. This was injected at the start of the sequence and subsequently every 10 samples throughout the LC/MS/MS analysis.

Metabolites were analyzed using a Thermo Scientific ICS-5000+ ion chromatography system coupled directly to a Q-Exactive HF Hybrid Quadrupole-Orbitrap mass spectrometer with a HESI II electrospray ionisation source (Thermo Scientific). The ICS-5000+ HPLC system incorporated an electrolytic anion generator (KOH) which was programmed to produce an OH^--^ gradient over 37 min for anion exchange chromatography. An inline electrolytic suppressor removed the OH^--^ ions and cations from the post-column eluent prior to MS analysis (Thermo Scientific Dionex AERS 500). A 10 μL partial loop injection was used for all analyses and the chromatographic separation was performed using a Thermo Scientific Dionex IonPac AS11-HC 2 × 250 mm, 4 μm particle size column with a Dionex Ionpac AG11-HC 4 μm 2x50 guard column inline. The IC flow rate was 0.250 mL/min. The total run time was 37 min and the hydroxide ion gradient comprised as follows: 0mins, 0mM; 1min, 0mM; 15mins, 60mM; 25mins, 100mM; 30mins, 100mM; 30.1mins, 0mM; 37mins, 0mM. Analysis was performed in negative ion mode using a scan-range from 80-900 and resolution set to 70,000. The tune file source parameters were set as follows: Sheath gas flow 60 mL/min; Aux gas flow 20 mL/min; Spray voltage 3.6v; Capillary temperature 320°C; S-lens RF value 70; Heater temperature 450°C. AGC target was set to 1e6v ions and the Max IT value was 250ms. The column temperature was kept at 30°C throughout the experiment. Full scan data were acquired in continuum mode.

Raw data files were processed using ProgenesisQI (Waters, Elstree). This process included alignment of retention times, identified the presence of natural abundance isotope peaks, identified adducts forms and was then used to identify compounds present. The retention times and other measurable characteristics for each metabolite were confirmed by comparing values from the experimental data with the same values from the analysis of authentic standards for each metabolite. The measured criteria compared where a combination of accurate mass analysis (\< 5ppm), retention time (+/− 15 s), fragmentation pattern and isotope pattern matching (\> 90%). Principal Component Analysis was also performed using ProgenesisQI from peas representing all 4215 compounds measured with a %CV \< 30 in the quality control samples (normalized to all compounds).

For lipidomics, 5x10^6^ cells were homogenized in 400 μl of 50% MeOH/H~2~O in a beads beater tube. Myristic-acid-14,14,14-d~3~ (1mg/ml) standard was spiked at ratio 1 μg/5x10^6^ cells and samples were vortexed for 5 min after adding 1 mL of tert-butyl methyl ether (MTBE). After centrifugation at 13,000 RPM supernatants were collected into a 5:1 MeOH/H~2~O solution. The aqueous phase was dried in a speedvac and combined with the dried MeOH pellet. For rederivatization, dried metabolite extraction was re-suspended in 20 μg/ul MOX (volume 50 μl) and reacted at 30°C for 90 min on vortex. 30 μl of pyridine and 70 μl of MSTFA were added to react at 60°C for 60 min before direct injection into GCxGC-MS system comprising of a gas chromatograph coupled to a quadrupole mass spectrometer (Shimadzu GCMS QP2010 Ultra) and a Shimadzu AOC-20i/s auto sampler as described. The first dimension separation was carried out on a SHM5MS capillary column (30 mÅ∼0.25 mm i.d.Å∼0.25 μm film thickness, Shimadzu) while the second dimension separation was on a BPX-50 capillary column (5 mÅ∼0.15 mm i.d.Å∼0.15 μm film thickness, SGE). Helium gas was used as a carrier gas at a 73 psi constant inlet head pressure. The modulation period was set as 6 s. The samples were injected at 280°C in different split ratios (between 1:1 to 1:200). The oven temperature was programed from 60°C to 320°C at 10°C/min and held at 320°C for 8 min. The interface temperature to the mass spectrometer was set at 330°C and ion source was heated at 230°C. The MS was operated at scan speeds between 5000 and 20,000 amu covering a range of m/z 45--600. Electron Ionization spectra were recorded at 70 eV.

### Metabolic flux analysis {#sec4.4.6}

The real-time extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured using a XF 96 extracellular flux analyzer (Seahorse Bioscience). 5 × 10^4^ 32D cells (CRISPR-*Atg7*^--/--^ and *Atg7*^+/+^ clones) or 2 × 10^5^ freshly isolated Ly6G^+^ BM neutrophils were washed twice in RPMI 1640 without sodium bicarbonate, 20 mM glucose, 1% FCS, 2mM pyruvate and seeded in corresponding assay medium in a XF plate coated with poly-L-lysine (Sigma). Cells were rested for 1 hour at 37°C before analysis. Two independent experiments were performed with at least four independent replicates per group.

### Bacterial killing assay {#sec4.4.7}

Neutrophil intracellular anti-bacterial activity was assessed using the lysostaphin protection assay. *S. aureus* (NTCC 6571) were freshly cultured and opsonized with mouse serum (final concentration 12.5% in RPMI1640) at 37°C for 30 min. Mouse BM-derived Ly6G^+^ granulocytes (2.5x10^5^ cells/well) were infected in a 96-well round-bottom plate in 25 μL RPMI1640 + 10% FCS at MOI of 10 bacteria / neutrophil. Following 45 min of infection, cells were washed with warm PBS and cultured in RPMI + 10% FCS containing 100 μg/mL lysostaphin at 37°C. After 45 min, neutrophils were washed twice with PBS and lysed in 1%-Triton X-100 in dH~2~O. Lysate was serially diluted, plated on agar plates by track method and CFU were counted next day. Results were scored as absolute numbers of CFU per ml, with a minimum of 50 colonies counted per group in four independent replicates.

### Phagocytosis assay {#sec4.4.8}

Neutrophil phagocytosis was assessed by flow-cytometric quantification of fluorescent bead uptake during 1 hour incubation in the presence of 1 μg/ml LPS. pH-sensitive phRodo zymosan-beads (Invitrogen) were used except where indicated otherwise. Surface marker staining was performed after phagocytosis and data quantified as % of cells bead+ from three independent experiments with four mice per group.

### q-PCR {#sec4.4.9}

RNA was extracted using RNeasy Kit (QIAGEN) and quantified using a Nanodrop spectrophotometer (Thermo Scientific). RNA was reverse transcribed (RT) using a High Capacity RNA to cDNA kit (Applied Biosystems (AB)). Resulting cDNA was stored at −20°C. Real-time quantitative PCR using comparative Ct method (ΔΔCt) was utilized to evaluate gene expression using validated TaqMan probes (AB) on a 7500 Fast Real-time PCR machine (AB). Conditions: (1) 50°C, 2 min; (2) 95°C, 10 min; (3) 95°C 15 s; (4) 60°C 1 min; 40 cycles of 3--4. All results were normalized to actin, gapdh and hprt expression after which the best housekeeping gene was selected for further analysis. The assay IDs for the primers of the analyzed genes are as follows: Mm00504340_m1 (*Atg5*), Mm00512209_m1 (*Atg7*), Mm01545399_m1 (*Hprt*), Mm99999915_g1 (*Gapdh*), Mm00607939_s1 (*Actin*), Mm01298424_m1 (*Mpo*), Mm00442991_m (*Mmp9*), Mm00434787_m1 (*Ltf*), Mm00514283_s1 (*Cebpa*),

### Fluidigm gene expression analysis {#sec4.4.10}

32D CRISPR-*Atg7*^--/--^ and *Atg7*^+/+^ clones were flow-sorted (two hundred cells/population) from independent clones into OneStep lysis buffer (Invitrogen). For *in vivo* experiments, 100 bone marrow cells were sorted per population. RNA was reverse transcribed and cDNA was pre-amplified using the CellsDirect OneStep q-RT kit (Invitrogen). The selected autophagy, apoptotic and metabolic genes were amplified and analyzed for expression using a dynamic 48x48 array (Biomark Fluidigm) as previously described ([@bib49]). Data were analyzed using the 2^-ΔΔCt^ method, and all results were normalized to *Actin*, *B2m* and *Hprt* expression after which the best housekeeping gene was selected for further analysis. Biological replicates represent individual mice in each experiment.

### ATP levels {#sec4.4.11}

Total bone marrow cells were isolated from *Cebpa-cre*^+^ x *Atg7*^f/f^ and littermate controls. Ly6G^+^ cells (which include MM, BC, PMN) were purified using MACS columns (Miltenyi Biotec). Cell count was normalized to 1x10^6^ cells per sample and ATP levels from cell pellets were determined by using the luciferase based ATP Bioluminescence Assay Kit HS II (Roche Applied Science). ATP concentration was calculated from intersection of sample luminescence values with ATP standard. Independent biological replicates represent individual mice in each experiment.

### L-lactate and glucose quantification {#sec4.4.12}

32D CRISPR-*Atg7*^--/--^ and *Atg7*^+/+^ clones were cultured in RPMI 1640 (containing 2mg/mL Glucose) with 1% FCS, 2 mM L-glutamine, 100 U/ml Pen-Strep. In order to induce neutrophil differentiation, 1x10^6^ cells/ml were seeded in 96-well plates with medium supplemented with 100 ng/ml recombinant murine G-CSF (peprotech). At day 3, medium was supplemented with fresh 100 ng/mL G-CSF. Cells and supernatant were harvested at indicated time points and supernatants analyzed for glucose levels and L-lactate levels following the Glucose (GO) Assay Kit (GAGO-20, Sigma) and the Glycolysis Cell-Based Assay Kit (\#600450, Cayman Chemicals). Cells were lysed in NP40 buffer and protein was quantified using Pierce BCA Protein Assay Kit (Sigma). Glucose consumption and L-lactate levels were normalized to protein levels for each well individually. Each assay representative of at least two independent experimental repeats.

### Western blot {#sec4.4.13}

1 × 10^6^ 32D CRISPR-*Atg7*^--/--^ and *Atg7*^+/+^ myeloblasts or after indicated time of neutrophil differentiation, or 2 × 10^6^ purified primary Ly6G^+^ neutrophils were lysed on ice using 100 μL 1 × RIPA lysis buffer. Protein concentration in supernatant was measured using BCA Protein Assay Kit (Thermo Scientific), and reducing Laemmli Sample Buffer was added to make protein samples for SDS-PAGE. 30--50 μg protein per lane were separated on 4%--12% SDS-PAGE and transferred to PVDF membrane (Millipore). After blocking with 5% skim milk, the membrane was blotted using the following primary antibodies: LC3 (L8918, Sigma) (1:1000), beta-Actin (Cell-Signaling) (1:20,000) and IRDye secondary antibodies (LI-COR, Lincoln) (1:15,000).

### Microscopy {#sec4.4.14}

For transmission electron microscopy (TEM), 1x10^6^ cells were sorted by flow cytometry based on CD11b and Ly6G expression and fixed in 2.5% glutaraldehyde, 4% PFA in 0.1M PIPES buffer, pH 7.2 for approximately 1 hr at room temperature then stored at 4°C in the fixative for 36 hr. Pellets were washed in 0.1M PIPES buffer pH 7.2 for 3x15 min, then in 100 mM glycine in the same buffer for 20 min followed by 15 min in 0.1M PIPES buffer. Cells were resuspended in warm 2.5% low melting point agarose in 0.1M PIPES and spun at 10,000 rpm for 1 min. Once set, cut agarose was incubated in 1% osmium tetroxide in 0.1M PIPES for 1 hr at 4°C, then washed with water for 20 min. Samples were incubated in 0.5% uranyl acetate in water overnight at 4°C and then taken through a graded ethanol series (30%, 50%, 70%, 80%, 90% and 95% ethanol for 10 min each on ice, then 100% ethanol for 90 min on ice, with 3 solution changes during this time). Samples were gradually infiltrated with Agar100 epoxy resin, starting with 25% resin for 1 hr, 50% resin for 2 hr, 75% resin for 1 hr and 100% resin overnight, followed by two changes with fresh 100% resin the next day before embedding by in Beem capsules and polymerization for 48 hr at 60°C. Ultrathin (90 nm) were obtained using a Leica UC7 ultramicrotome with a diamond knife (Diatome) and placed on 200 mesh copper grids, then post-stained with Reynold's lead citrate for 5 min, and imaged on a FEI Tecnai 12 TEM operated at 120 kV using a Gatan OneView CMOS camera.

For confocal microscopy, primary bone marrow neutrophil precursors were separated by flow cytometry as described and stained with Bodipy at 1000 ng/ml for 20 min at 37°C. Cells were cytospun on glass slides and mounted in the presence of DAPI (Vectashield). Images were acquired on a ZEISS 880 inverted confocal microscope + LSM120C with a 63x plan-apochromat objective. All images were taken with identical laser setup and voltage settings.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

p values were determined by one-way or two-way ANOVA with Tukey\'s post-tests, unpaired Student's t test or nonparametric Mann--Whitney test as indicated in figure legends. Differences were considered statistically significant when p \< 0.05 (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001). Data are shown as mean ± s.e.m. except indicated otherwise in figure legends. Statistics were calculated using GraphPad Prism 7 software. For all histological quantifications, histologists were 'blinded' to allocation of animals and experimental groups.
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